MAGEA3 and neoplasm: PeptiCRAd is a cancer vaccine platform combining OAd with polylysine-modified tumor antigens.13, 14, 15 PeptiCRAd-1 is a cancer vaccine that consists of VALO-D102 coated with human leukocyte antigen (HLA)-I epitopes from two known tumor antigens: the cancer-testis antigen NY-ESO-1 and human melanoma antigen MAGE-A3.